Format

Send to

Choose Destination
Trials. 2020 Feb 3;21(1):135. doi: 10.1186/s13063-020-4077-x.

Intratympanic versus intravenous corticosteroid treatment for sudden sensorineural hearing loss in diabetic patients: proposed study protocol for a prospective, randomized superiority trial.

Yang W1,2, Li X3, Zhong J1,2, Mei X1,2, Liu H1,2, Yang L1, Lu L4, Hu H5,6.

Author information

1
Department of Otorhinolaryngology, Peking University Shenzhen Hospital, Shenzhen, China.
2
Hearing and Balance Function Medical Engineering Laboratory, Shenzhen, China.
3
The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
4
Clinical Research and Data Centre, South China Research Centre for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China. lulimingleon@126.com.
5
Department of Otorhinolaryngology, Peking University Shenzhen Hospital, Shenzhen, China. hyihu@sina.com.
6
Hearing and Balance Function Medical Engineering Laboratory, Shenzhen, China. hyihu@sina.com.

Abstract

BACKGROUND:

Diabetes mellitus is associated with risk of sudden sensorineural hearing loss (SSNHL). Systemic and intratympanic corticosteroids are the two primary treatments for SSNHL in patients with diabetes mellitus. The benefit of intratympanic compared to systemic treatment is the reduced systemic steroid exposure and associated systemic adverse effects. Intratympanic corticosteroid administration may have potential benefits over standard systemic therapies.

METHODS/DESIGN:

The proposed study is a prospective, randomized superiority trial. A total of 96 patients (48 in each group) will be randomized into the experimental or control group. Patients in the experimental group will receive four 1-mL doses of 40 mg/mL of methylprednisolone over a 1-week period, with a dose administered every 2 days via tympanic membrane injection into the middle ear. The control group will be administered intravenous methylprednisolone (1 mg/kg/day, maximal dose 60 mg/day) for 5 days. The primary outcome for this study is the change in hearing threshold from the first audiogram to the 30-day follow-up audiogram. Secondary outcome measures will include pure-tone average (PTA) at 90-day follow up, visual analog tinnitus scale, visual analog vertigo scale, visual analog aural fullness scale, fasting blood glucose and 2-h postprandial blood glucose during treatment, and the change in glycosylated hemoglobin (HbA1C) levels. Vital signs and otological physical examination will be performed at each follow-up visit.

DISCUSSION:

The efficacy and safety of intratympanic methylprednisolone compared to intravenous methylprednisolone will be investigated in patients with diabetes mellitus and SSNHL. This trial may provide strong evidence for the efficacy and safety of intratympanic corticosteroid treatment and important clinical information for the treatment of patients with diabetes mellitus and SSNHL.

TRIAL REGISTRATION:

ChiCTR, ChiCTR1800015954. Registered on 2 May 2018, Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=25326.

KEYWORDS:

Diabetes; Intratympanic methylprednisolone; Intravenous methylprednisolone; Randomized controlled trial; Sudden sensorineural hearing loss

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center